Sefa Resim
Research Subjects
Research Interests
Sefa Resim has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
Ahmet Ciftci
Department of Urology, KSU Medical School and
1 shared publicationHasan Ekerbicer
Department of Public Health, KSU Medical School, Kahramanmaras, Turkey
1 shared publication
Latest Publications
- Open Access
- 25 July 2005
- Published by Wiley in International Journal of Urology
- Vol. 12 (7) , 615-620
Effect of tamsulosin on the number and intensity of ureteral colic in patients with lower ureteral calculus
Background: We aimed to objectively determine whether tamsulosin as an α1‐blocker was effective in patients who had ureterolithiasis located in the lower part of the ureter.Methods: Sixty patients with lower ureteral calculi (juxtavesical or intramural portion) were included in the present study. Conservative treatment, such as hydration and tenoxicam as a non‐steroidal anti‐inflammatory drug, was given to group 1 (30 patients). Group 2 (30 patients) was given tamsulosin (0.4 mg daily) in addition to the conservative treatment. All patients were followed up and questioned about the numbers and intensity of ureteral colic, and the rates of spontaneous passage after the procedure.Results: Spontaneous passage was observed in 22 of the 30 patients in group 1 (73.3%) and 26 of the 30 patients in group 2 (86.6%). The difference within groups 1 and 2 was not significant (P = 0.196). The difference between both groups was not statistically significant either, with the stone diameter being 6 mm (P = 0.635) or >6 mm (P = 0.407). As group 1 patients were passing their stones, they had more ureteral colic episodes than group 2 patients. This difference was statistically significant and correlated well with the administration of tamsulosin (P = 0.038). Group 1 patients reported higher scores according to a visual analog scale than group 2 patients. Also, this difference was statistically significant (P = 0.000).Conclusions: We think that the treatment of α1‐blockers decreased the number of ureteral colic episodes and the intensity of pain during spontaneous passage at the lower ureteral calculi. Also, it will be beneficial to patients’ quality of life.
- 25 July 2005
- Published by Wiley in International Journal of Urology
- Vol. 12 (7) , 615-620
Open AccessEffect of tamsulosin on the number and intensity of ureteral colic in patients with lower ureteral calculus
Background: We aimed to objectively determine whether tamsulosin as an α1‐blocker was effective in patients who had ureterolithiasis located in the lower part of the ureter.Methods: Sixty patients with lower ureteral calculi (juxtavesical or intramural portion) were included in the present study. Conservative treatment, such as hydration and tenoxicam as a non‐steroidal anti‐inflammatory drug, was given to group 1 (30 patients). Group 2 (30 patients) was given tamsulosin (0.4 mg daily) in addition to the conservative treatment. All patients were followed up and questioned about the numbers and intensity of ureteral colic, and the rates of spontaneous passage after the procedure.Results: Spontaneous passage was observed in 22 of the 30 patients in group 1 (73.3%) and 26 of the 30 patients in group 2 (86.6%). The difference within groups 1 and 2 was not significant (P = 0.196). The difference between both groups was not statistically significant either, with the stone diameter being 6 mm (P = 0.635) or >6 mm (P = 0.407). As group 1 patients were passing their stones, they had more ureteral colic episodes than group 2 patients. This difference was statistically significant and correlated well with the administration of tamsulosin (P = 0.038). Group 1 patients reported higher scores according to a visual analog scale than group 2 patients. Also, this difference was statistically significant (P = 0.000).Conclusions: We think that the treatment of α1‐blockers decreased the number of ureteral colic episodes and the intensity of pain during spontaneous passage at the lower ureteral calculi. Also, it will be beneficial to patients’ quality of life.